Answers are grounded in this paper and cite their sources.
// Jing Xiong 1, 2 , Ying Liu 3 , Shengjun Luo 1 , Li Jiang 1 , Yang Zeng 1 , Zhixiong Chen 1 , Xiaobo Shi 1 , Bufan Lv 1 , Wei Tang 1 1 Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 2 Departmentof Urology and Andrology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China 3 Department of Preventive Medicine, School of Public Health and Management, Hubei University of Medicine, Shiyan, Hubei Province, China Correspondence to: Wei Tang, email: tangwei2060@163.com Keywords: long non-coding RNAs, HEIRCC, renal cell carcinoma, prognosis, EMT Received: June 30, 2016 Accepted: November 04, 2016 Published: December 24, 2016 ABSTRACT Increasing evidence indicates that long non-coding RNAs (lncRNAs) have been associated with cancer development. However, the contributions of lncRNAs to renal cell carcinoma (RCC) remain poorly characterized. Here, we identified a novel lncRNA, termed HEIRCC, which was up-regulated in RCC tissues through lncRNA microarray analysis and subsequent validation in 60 RCC clinical specimens and cell lines. The high expression of HEIRCC is associated closely with the clinical pathology features such as larger tumor size, poor differentiation, lymphatic metastasis. In vitro assays revealed that HEIRCC knockdown could inhibit cell proliferation, trigger late apoptosis, suppress cell migration and invasion. We further demonstrated that depletion of HEIRCC reduce the epithelial to mesenchymal transition (EMT) program by regulating expression levels of EMT-associated markers in RCC cells. Thus, HEIRCC might be act as an important regulator of EMT in RCC progression and might be a novel therapeutic target for the advanced RCC therapy.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: